EPX-100 Shows Promising Seizure Reduction in Ongoing Open-Label Extension Louie Pasculli

Published Date: 13 Dec 2025

New data from the open-label extension of Harmony Biosciences’ Phase 3 ARGUS trial show that EPX-100 (clemizole) achieved a median 50% reduction in countable motor seizures in patients with Dravet Syndrome.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Next Day Mood Is Affected by Ability to Recover From Work.

2.

Enhanced CAR T cell therapy offers new strategy for lymphoma

3.

With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.

4.

Decrease seen in in situ breast cancer since 2009

5.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot